¿Se puede utilizar la determinación del pico flujo de tos para valorar la capacidad tusígena en enfermedades respiratorias obstructivas graves? / Can cough peak flow be used to assess cough capacity in severe obstructive respiratory diseases?

Introducción: La valoración de la capacidad tusígena se realiza con la medición del flujo espiratorio máximo durante la tos (peak-flow tos [PFT]). Sin embargo, esta valoración podría alterarse por enfermedades con obstrucción espiratoria de la vía aérea. El objetivo fue valorar la medición de la capacidad tusígena mediante PFT en pacientes con enfermedad pulmonar obstructiva crónica (EPOC), así como las correlaciones con la función pulmonar, muscular respiratoria y orofaríngea. Métodos: Se seleccionaron los pacientes con EPOC y con enfermedad neuromuscular, así como los sujetos sanos a los que se había realizado una medición de la fuerza de los músculos respiratorios de forma asistencial. De esta población, se analizaron los valores de la función respiratoria, así como la fuerza muscular orofaríngea. En un subgrupo de pacientes con EPOC se realizó el estudio de deglución por videofluoroscopia. Resultados: Se incluyeron 307 sujetos (59,3% EPOC, 38,4% enfermedades neuromusculares y 2,3% sanos). En el grupo EPOC, el PFT se encontraba disminuido de forma estadísticamente significativa comparado tanto con el grupo de los sanos como con los enfermos neuromusculares. El 70% de los EPOC tenían una disminución patológica del PFT. Solamente, existía una correlación directa entre el PFT con el grado de obstrucción bronquial y la fuerza de los músculos espiratorios. No se encontró alteración de la función de los músculos inspiratorios ni orofaríngeos. Conclusiones: La utilización del PFT en los pacientes con EPOC no refleja la capacidad tusígena ya que se ve influenciada por el grado de obstrucción bronquial. Por tanto, se deberían valorar nuevas pruebas diagnósticas para la medición de la capacidad tusígena, fundamentalmente, en los pacientes que coexistan enfermedades neuromusculares y patología obstructiva bronquial grave.(AU)

Introduction: Cough capacity is assessed by measuring cough peak flow (CPF). However, this assessment could be altered by obstructive airway diseases. The aim was to assess measurement of cough capacity by CPF in patients with chronic obstructive pulmonary disease (COPD), as well as correlations with pulmonary, respiratory muscle, and oropharyngeal function. Methods: Patients with COPD, and with neuromuscular disease, were selected as well as healthy subjects who had undergone respiratory muscle strength measurement in a healthcare setting. From this population, respiratory function values and lung and oropharyngeal muscle function were analysed. A subgroup of COPD patients underwent a videofluoroscopic swallow study. Results: Three hundred and seven subjects were included (59.3% COPD, 38.4% neuromuscular diseases, and 2.3% healthy). CPF was found to be statistically significantly decreased in the COPD group compared to both the healthy and neuromuscular disease groups. Of the COPD patients, 70% had a pathological decrease in CPF. There was only a direct correlation between CPF with the degree of bronchial obstruction and expiratory muscle strength. No alteration of inspiratory or oropharyngeal muscle function was found. Conclusions: The use of CPF in COPD patients does not reflect cough capacity as it is influenced by the degree of bronchial obstruction. Therefore, new diagnostic tests to measure cough capacity should be considered, especially in patients with coexisting neuromuscular diseases and severe bronchial obstructive disease.(AU)

[Can cough peak flow be used to assess cough capacity in severe obstructive respiratory diseases?] / ¿Se puede utilizar la determinación del pico flujo de tos para valorar la capacidad tusígena en enfermedades respiratorias obstructivas graves?

INTRODUCTION: Cough capacity is assessed by measuring cough peak flow (CPF). However, this assessment could be altered by obstructive airway diseases. The aim was to assess measurement of cough capacity by CPF in patients with chronic obstructive pulmonary disease (COPD), as well as correlations with pulmonary, respiratory muscle, and oropharyngeal function. METHODS: Patients with COPD, and with neuromuscular disease, were selected as well as healthy subjects who had undergone respiratory muscle strength measurement in a healthcare setting. From this population, respiratory function values and lung and oropharyngeal muscle function were analysed. A subgroup of COPD patients underwent a videofluoroscopic swallow study. RESULTS: Three hundred and seven subjects were included (59.3% COPD, 38.4% neuromuscular diseases, and 2.3% healthy). CPF was found to be statistically significantly decreased in the COPD group compared to both the healthy and neuromuscular disease groups. Of the COPD patients, 70% had a pathological decrease in CPF. There was only a direct correlation between CPF with the degree of bronchial obstruction and expiratory muscle strength. No alteration of inspiratory or oropharyngeal muscle function was found. CONCLUSIONS: The use of CPF in COPD patients does not reflect cough capacity as it is influenced by the degree of bronchial obstruction. Therefore, new diagnostic tests to measure cough capacity should be considered, especially in patients with coexisting neuromuscular diseases and severe bronchial obstructive disease.

Manejo de secreciones no invasivo en un paciente con Esclerosis Lateral Amiotrófica no colaborador, ¿dónde está el límite? A propósito de un caso / Non invasive mucus drainage in a non-collaborate Amyotrophic Lateral Sclerosis patient. Where the limit is? A case report

Las complicaciones respiratorias son una de las causas de hospitalización más frecuente, e incluso de muerte, en pacientes con enfermedad neuromuscular. El seguimiento multidisciplinar tiene efectos positivos sobre la supervivencia y la calidad de vida en estos pacientes. Este caso supuso un reto terapéutico para el manejo de secreciones bronquiales, por ser un paciente con Esclerosis Lateral Amiotrófica no colaborador y que rechazaba las medidas invasivas. Tras un primer intento fallido de adaptación al sistema mecánico de tos convencional, se modificó la interfase usando una boquilla de tipo buzo invertida, introducida entre los dientes durante la aplicación del equipo con mascarilla nasobucal. Se consiguieron muestras de esputo, lo que nos permitió tratar las infecciones respiratorias con el antibiótico específico. Además, el seguimiento se realizó por videollamada, sin necesidad de desplazar al paciente hasta el hospital. El equipo multidisciplinar se adaptó a las necesidades del paciente tratando de forma novedosa y eficaz las infecciones respiratorias. Además, el uso de nuevas tecnologías evitó ingresos hospitalarios, a pesar de ser un paciente gran dependiente.(AU)

Respiratory complications are one of the most frequent causes of hospitalization and even death in patients with neuromuscular diseases. Multidisciplinary follow-up has been shown to have positive effects on survival and quality of life in these patients. The present case represented a therapeutic challenge in order to manage respiratory secretions in a non-collaborate Amyotrophic Lateral Sclerosis patient due to the negative to accept invasive strategies to cope with respiratory infections. Despite a first failed approach in the adaptation to a mechanical assisted cough device, then a modification in the interfase allowed to mobilize secretions and it was also possible to analyze them and use the correct antibiotic treatment. Moreover, a remotely follow-up was done to handle situations, like respiratory tract infections, whenever possible, without requesting the patient to move to the hospital. The multidisciplinary unit team adapted to his needs offering a newest and efficacy strategy to cope with respiratory infections. Indeed, the use of new technologies avoided in a high dependent patient to require hospitalizations.(AU)

Efectos en población sana de la terapia con oscilación de alta frecuencia sobre la pared torácica (HFCWO) a nivel de la dinámica de gases pulmonares y de la mecánica respiratoria / Effects of high frequency chest wall oscillatory (HFCWO) therapy on gas exchange and ventilation in healthy participants

Introducción La fisioterapia respiratoria es parte imprescindible del tratamiento de las patologías hipersecretoras o con compromiso de la capacidad tusígena. Hasta el momento se desconoce el efecto del dispositivo de terapia de oscilación de alta frecuencia en la pared torácica (HFCWO) sobre la fuerza de los músculos respiratorios y los efectos sobre la mecánica respiratoria y la dinámica de los gases respiratorios. Por ello, el objetivo de este estudio fue describir estos tres aspectos en sujetos sanos. Métodos Se midió la fuerza de los músculos respiratorios en 25 sujetos antes e inmediatamente después de terapia con HFCWO. Durante la sesión, se midieron continuamente los parámetros de ventilación, la dinámica de los gases respiratorios y la frecuencia cardiaca. Se llevaron a cabo dos sesiones idénticas por sujeto, separadas 24h. Se registraron los síntomas durante la sesión y las molestias experimentadas mediante escala analógica visual (EVA). Resultados La terapia con HFCWO produce un incremento de la ventilación asociado con una alteración de la dinámica de los gases respiratorios. También se aumenta la frecuencia cardiaca, sin modificación de la oxigenación tisular. No se observaron efectos sobre la fuerza de los músculos respiratorios. Hasta un 20% de los participantes indicó molestias importantes (EVA≥5/10) durante la sesión. Conclusiones Durante la aplicación de HFCWO en sujetos sanos se produce incremento en la ventilación y ritmo cardiaco. Sin embargo, aparecen efectos indeseables sobre la dinámica de los gases respiratorios y un grado elevado de intolerancia por parte de los voluntarios y no hay efectos sobre la fuerza de los músculos respiratorios (AU)

Introduction Chest physiotherapy is an essential part of the treatment of respiratory diseases with increased respiratory secretion and ineffective cough. To date, there have been no studies on the effect of high frequency chest wall oscillatory (HFCWO) therapy on respiratory muscle strength, ventilation and gas exchange. The aim of this study was therefore to assess these three factors in healthy participants. Methods Respiratory muscle strength was measured before and immediately after HFCWO therapy in 25 healthy participants. During the treatment, we continuously measured ventilation parameters, gas exchange, oxygen saturation and heart rate. All participants underwent HFCWO sessions twice (with 24hours difference) with the same procedure. Symptoms during the session and discomfort were measured with the visual analog scale (VAS). Results HFCWO therapy produced a change in breathing pattern with increased ventilation associated with altered gas exchange. Heart rate also increased, with no changes in oxygenation. There was no effect, either beneficial or deleterious, on the strength of respiratory muscles. Up to 20% of participants reported substantial discomfort (VAS≥5/10) during the session. Conclusions This study shows that, during the application of HFCWO therapy in healthy participants, ventilation and heart rate increased. However, there were undesirable effects on gas exchange with a high degree of intolerance among volunteers, with no effects on respiratory muscle strength (AU)

[Effects of high frequency chest wall oscillatory (HFCWO) therapy on gas exchange and ventilation in healthy participants]. / Efectos en población sana de la terapia con oscilación de alta frecuencia sobre la pared torácica (HFCWO) a nivel de la dinámica de gases pulmonares y de la mecánica respiratoria.

INTRODUCTION: Chest physiotherapy is an essential part of the treatment of respiratory diseases with increased respiratory secretion and ineffective cough. To date, there have been no studies on the effect of high frequency chest wall oscillatory (HFCWO) therapy on respiratory muscle strength, ventilation and gas exchange. The aim of this study was therefore to assess these three factors in healthy participants. METHODS: Respiratory muscle strength was measured before and immediately after HFCWO therapy in 25 healthy participants. During the treatment, we continuously measured ventilation parameters, gas exchange, oxygen saturation and heart rate. All participants underwent HFCWO sessions twice (with 24hours difference) with the same procedure. Symptoms during the session and discomfort were measured with the visual analog scale (VAS). RESULTS: HFCWO therapy produced a change in breathing pattern with increased ventilation associated with altered gas exchange. Heart rate also increased, with no changes in oxygenation. There was no effect, either beneficial or deleterious, on the strength of respiratory muscles. Up to 20% of participants reported substantial discomfort (VAS≥5/10) during the session. CONCLUSIONS: This study shows that, during the application of HFCWO therapy in healthy participants, ventilation and heart rate increased. However, there were undesirable effects on gas exchange with a high degree of intolerance among volunteers, with no effects on respiratory muscle strength.

Normativa SEPAR sobre disfunción muscular de los pacientes con enfermedad pulmonar obstructiva crónica / Guidelines for the evaluation and treatment of muscle dysfunction in patients with chronic obstructive pulmonary disease

La disfunción muscular de pacientes con enfermedad pulmonar obstructiva crónica (EPOC) constituye una de las comorbilidades más importantes, con repercusiones negativas en su capacidad de ejercicio y calidad de vida. En la presente normativa se ha resumido la literatura publicada más recientemente sobre los diferentes aspectos del tema y se ha utilizado también la escala Grading of Recommendations Assessment, Development, and Evaluation (GRADE) de recomendaciones sobre el grado de evidencia de las diferentes propuestas de la normativa. Respecto a una población control, se estima que en un tercio de los pacientes EPOC la fuerza del cuádriceps es un 25% inferior incluso en estadios precoces de su enfermedad. Aunque tanto los músculos respiratorios como los de las extremidades están alterados, estos últimos suelen verse mayormente afectados. Diversos factores y mecanismos biológicos están involucrados en la disfunción muscular de los pacientes. Se proponen diversas pruebas para evaluar y diagnosticar el grado de afectación de los músculos respiratorios y de las extremidades (periféricos), así como identificar la capacidad de esfuerzo de los pacientes (prueba de marcha de 6min y cicloergometría). Se describen también las posibles estrategias terapéuticas vigentes que incluyen las diversas modalidades de entrenamiento y de soporte farmacológico y nutricional.(AU)

In patients with chronic obstructive pulmonary disease (COPD), skeletal muscle dysfunction is a major comorbidity that negatively impacts their exercise capacity and quality of life. In the current guidelines, the most recent literature on the various aspects of COPD muscle dysfunction has been included. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) scale has been used to make evidence-based recommendations on the different features. Compared to a control population, one third of COPD patients exhibited a 25% decline in quadriceps muscle strength, even at early stages of their disease. Although both respiratory and limb muscles are altered, the latter are usually more severely affected. Numerous factors and biological mechanisms are involved in the etiology of COPD muscle dysfunction. Several tests are proposed in order to diagnose and evaluate the degree of muscle dysfunction of both respiratory and limb muscles (peripheral), as well as to identify the patients' exercise capacity (six-minute walking test and cycloergometry). Currently available therapeutic strategies including the different training modalities and pharmacological and nutritional support are also described.(AU)

Place of death in patients with amyotrophic lateral sclerosis.

UNLABELLED: Amyotrophic lateral sclerosis (ALS) is a degenerative neurological disorder that affects motor neurons. Involvement of respiratory muscles causes the failure of the ventilator pump with more or less significant bulbar troubles. ALS course is highly variable but, in most cases, this disease entails a very significant burden for patients and caregivers, especially in the end-of-life period. In order to analyze the characteristics of ALS patients who die at home (DH) and in hospital (DHosp) and to study the variability of clinical practice, a retrospective medical records analysis was performed (n=77 from five hospitals). VARIABLES: time elapsed since the onset of symptoms and the beginning of ventilation, characteristics of ventilation (device, mask and hours/day), and support devices and procedures. RESULTS: In all, 14% of patients were ventilated by tracheotomy. From the analysis, 57% of patients were of DH. Mean time since the onset of symptoms was 35.93±25.89 months, significantly shorter in patients who DHosp (29.28±19.69 months) than DH (41.12±29.04) (p=0.044). The percentage of patients with facial ventilation is higher in DHosp (11.4% vs 39.4%, p<0.005). DH or not is related to a set of elements in which health resources, physician attitudes and support resources in the community play a role in the decision-making process. There is great variability between countries and between hospitals in the same country. Given the variability of circumstances in each territory, the place of death in ALS might not be the most important element; more important are the conditions under which the process unfolds.

Interpretation of the approximate entropy using fixed tolerance values as a measure of amplitude variations in biomedical signals.

A new method for the quantification of amplitude variations in biomedical signals through moving approximate entropy is presented. Unlike the usual method to calculate the approximate entropy (ApEn), in which the tolerance value (r) varies based on the standard deviation of each moving window, in this work ApEn has been computed using a fixed value of r. We called this method, moving approximate entropy with fixed tolerance values: ApEn(f). The obtained results indicate that ApEn(f) allows determining amplitude variations in biomedical data series. These amplitude variations are better determined when intermediate values of tolerance are used. The study performed in diaphragmatic mechanomyographic signals shows that the ApEn(f) curve is more correlated with the respiratory effort than the standard RMS amplitude parameter. Furthermore, it has been observed that the ApEn(f) parameter is less affected by the existence of impulsive, sinusoidal, constant and Gaussian noises in comparison with the RMS amplitude parameter.

Muscle dysfunction and exercise limitation in adolescent idiopathic scoliosis.

Adolescent idiopathic scoliosis (AIS) can lead to ventilatory restriction, respiratory muscle weakness and exercise limitation. However, both the causes and the extent of muscle dysfunction remain unclear. The aim of our study is to describe muscle weakness and its relationship to lung function and tolerance to exercise in AIS patients. Lung and muscle function, together with exercise capacity, were assessed in 60 patients with pronounced spinal deformity (>40 degrees) and in 25 healthy volunteers. Patients with AIS had only mild to moderate abnormal ventilatory patterns, the most frequent of which were restrictive abnormalities. The function of respiratory and limb muscles and exercise capacity were below normal limits in AIS patients, and were significantly lower than in controls. Exercise capacity was found to correlate with the function of inspiratory, expiratory, upper limb and lower limb muscles which, in addition, were reciprocally interrelated. Multivariate analysis showed that lower limb muscle function is the main contributor to exercise intolerance. There appeared to be no connection between spinal deformity and lung function, muscle function or exercise capacity. We conclude that AIS patients show generalised muscle dysfunction which contributes to the reduction in their exercise capacity, even in the absence of severe ventilatory impairment.

Upregulation of pro-inflammatory cytokines in the intercostal muscles of COPD patients.

Muscle dysfunction is a characteristic feature of chronic obstructive pulmonary disease (COPD). Recent studies suggest that cytokines may operate as local regulators of both muscle function and regeneration. The aim of the present study was to characterise the expression of different cytokines in the external intercostal muscle of COPD. Muscle biopsies were obtained from 25 stable COPD patients and eight healthy controls. Local tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta, -6 and -10 expressions (real-time PCR and ELISA), sarcolemmal damage (immunohistochemistry), and the transcript levels of CD18 were assessed. Muscle TNF-alpha and IL-6 transcripts were significantly higher in COPD patients compared with controls, and IL-1beta and sarcolemmal damage showed a strong tendency in the same direction. Similar results were observed at protein level. The CD18 panleukocyte marker was similar in COPD and controls. Respiratory muscle function was impaired in COPD patients and it correlated to both the severity of lung function impairment and TNF-alpha muscle expression. Chronic obstructive pulmonary disease is associated with the upregulation of pro-inflammatory cytokines in the intercostal muscles. This phenomenon might be involved in respiratory muscle dysfunction.

Síndrome de bajo peso asociado a la EPOC en nuestro medio / Low-weight syndrome associated with COPD in our setting

INTRODUCCIÓN: La enfermedad pulmonar obstructiva crónica (EPOC) es una entidad de elevada prevalencia, con importantes consecuencias económicas y sanitarias, que derivan en gran parte de la limitación que la enfermedad comporta en la actividad y expectativas vitales del paciente. Uno de los factores recientemente implicados en las citadas limitaciones es la presencia de bajo peso asociada con la enfermedad. Aunque la causa no está clara, esta alteración parece afectar a un número importante de pacientes (entre el 25 y el 35 per cent según las series), al menos en el norte de Europa y los EE.UU. Sin embargo, existe la percepción de que la situación podría ser diferente en el área mediterránea. OBJETIVO: Aproximar la prevalencia del síndrome de bajo peso en pacientes con EPOC de nuestro entorno. MÉTODOS: Se revisaron las características antropométricas básicas de los pacientes con EPOC filiados funcionalmente en nuestro laboratorio a lo largo de los dos últimos años (2000-2001).RESULTADOS: De los 3.126 sujetos analizados, la prevalencia de un índice de masa corporal (IMC) por debajo de 20 kg/m2 fue de tan sólo el 6,6 per cent, cifra que se reducía al 3,1 per cent si el dintel escogido era el de 18 kg/m2. Este dato es aún más llamativo si se tiene en cuenta que casi la mitad de los pacientes evidenciaban enfermedad grave (volumen espiratorio forzado en el primer segundo [FEV1] inferior al 50 per cent ref). El IMC se correlacionó directamente con FEV1/FVC y transferencia del CO.CONCLUSIONES: Estos resultados sugieren que los pacientes con EPOC de nuestra área geográfica presentan características fenotípicas diferenciadas de las previamente descritas en otras latitudes. En concreto, una menor prevalencia del síndrome de bajo peso. Sin embargo, esta observación debe ser confirmada en estudios más amplios (AU)

[Low-weight syndrome associated with COPD in our setting]. / Síndrome de bajo peso asociado a la EPOC en nuestro medio.

UNLABELLED: The high prevalence of chronic obstructive pulmonary disease (COPD) has considerable economic and health-related impact. The consequences arise largely from limitations on a patient's activity and shortened life expectancy. Low body weight has recently been implicated as a factor affecting limitations. Although the reason is not clear, weight loss appears to affect many patients (from 25 to 35% in different series), at least in Europe and North America. However, the situation is thought to be different in the Mediterranean area. OBJECTIVE: To estimate the prevalence of the low weight syndrome in patients with COPD in our area. METHODS: COPD patient characteristics monitored by our laboratory over the last two years (2000 and 2001) were reviewed. RESULTS: The prevalence of a body mass index (BMI) less than 20 kg/m2 was only 6.6% among the 3,126 patients studied. That percentage fell to 3.1% with a cutoff of 18 kg/m2. The figure was even more striking if we consider that half the patients had severe disease (FEV1 < 50% of reference). BMI was directly related to FEV1/FC and CO transfer. CONCLUSIONS: These results suggest that COPD patients in our geographic area have characteristics that distinguish them from those previously described in other countries. Specifically, the prevalence of low weight syndrome in our area appears to be lower. However, larger studies should be performed to confirm this finding.